ICICI Direct: Granules India Q2 Review - Strong Growth Across Segments, Better Product Mix
Pills arranged for a photograph in Tokyo, Japan. (Photographer: Kiyoshi Ota/Bloomberg)

ICICI Direct: Granules India Q2 Review - Strong Growth Across Segments, Better Product Mix

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Granules India Ltd.’s Q2 revenues grew 22.7% YoY to Rs 858 crore on the back of strong growth across segments.

Formulations (finished drugs) grew 22.4% YoY to Rs 430 crore, active pharmaceutical ingredients grew 17.2% to Rs 255 crore and pharmaceutical formulation intermediates grew 32.6% to Rs 173 crore.

Ebitda margin improved 935 basis points YoY to 29.9% due to change in product mix, higher operational efficiency.

Ebitda grew 78.6% YoY to Rs 256 crore. Profit after tax grew 70.8% YoY to Rs 164 crore. Delta vis-a-vis Ebitda was mainly due to higher tax rate.

Click on the attachment to read the full report:

ICICI Direct Granules India Q2FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.